Real‐world effectiveness and persistence of golimumab as second‐line <scp>anti‐TNFα</scp> drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: <scp>GO‐BEYOND</scp>, a 12‐month prospective observational study-Reference-Cited by-同舟云学术

Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study

Published:2024-03 Issue:3 Volume:27 Page:
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J of Rheum Dis

Author:

D'Angelo Salvatore¹,Tirri Enrico²,Giardino Angela Maria³^ORCID,De Rosa Tiziana³,Matucci‐Cerinic Marco⁴⁵,Dagna Lorenzo⁵,Santo Leonardo⁶,Ciccia Francesco⁷,Frediani Bruno⁸,Govoni Marcello⁹,Pallavicini Francesca Bobbio¹⁰,Grembiale Rosa Daniela¹¹,Sedie Andrea Delle¹²,Mulè Rita¹³,Cantatore Francesco Paolo¹⁴,Foti Rosario¹⁵,Gremese Elisa¹⁶,Conigliaro Paola¹⁷,Salaffi Fausto¹⁸,Viapiana Ombretta¹⁹,Cauli Alberto²⁰,Giacomelli Roberto²¹,Arcarese Luisa²¹,Guggino Giuliana²²,Russo Romualdo²³,Puenpatom Amy²⁴,Capocotta Domenico²,Nacci Francesca²⁵,Anelli Maria Grazia²⁶,Picerno Valentina¹,Binetti Corrado³,Iannone Florenzo²⁶^ORCID,

Affiliation:

1. Istituto Reumatologico Lucano (I.Re.L) e Dipartimento Regionale di Reumatologia AOR San Carlo di Potenza Potenza Italy

2. UOSD di Reumatologia Ospedale San Giovanni Bosco Napoli Italy

3. Medical Affairs MSD Italia S.r.l. Roma Italy

4. A.O. Careggi Università Firenze Italy

5. Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR) IRCCS San Raffaele Scientific Institute, Vita‐Salute San Raffaele University Milan Italy

6. U.O.S. Reumatologia ASL BT—DSS 4 Barletta Italy

7. AOU Università degli Studi della Campania “Luigi Vanvitelli” Napoli Italy

8. UOC di Reumatologia Azienda Ospedaliero Universitaria Senese Siena Italy

9. AOU S. Anna di Ferrara, UOC Reumatologia, Dipartimento di Scienze Mediche Università di Ferrara Ferrara Italy

10. Fondazione IRCCS Policlinico San Matteo S.C. Reumatologia Pavia Italy

11. Rheumatology Research Unit, Dipartimento di Scienze della Salute Università degli studi “Magna Graecia” di Catanzaro Catanzaro Italy

12. U.O. Reumatologia Azienda Ospedaliero Universitaria Pisana Pisa Italy

13. UO Reumatologia IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Policlinico di Sant'Orsola Bologna Italy

14. UOC Reumatologia Universitaria, “Ospedali Riuniti” di Foggia Foggia Italy

15. A.O.U. Policlinico G. Rodolico‐S. Marco, U.O di Reumatologia Catania Italy

16. Fondazione Policlinico Universitario A. Gemelli‐IRCCS, Università Cattolica del Sacro Cuore Rome Italy

17. UOC Reumatologia, Dipartimento di Medicina dei Sistemi Università di Roma “Tor Vergata” Rome Italy

18. Clinica Reumatologica, Ospedale “C. Urbani” Università Politecnica delle Marche Ancona Italy

19. Ospedale Borgo Roma Policlinico G.B. Rossi, U.O.C. Reumatologia Verona Italy

20. Azienda Osped/Universitaria Policlinico Monserrato Cagliari Italy

21. UOC ImmunoReumatologia, Università CampusBio Medico di Roma Roma Italy

22. PROMISE Department University of Palermo Palermo Italy

23. AORN, A. Cardarelli U.O.S. Reumatologia Napoli Italy

24. Center for Observational and Real‐World Evidence, Merck & Co., Inc. Rahway New Jersey USA

25. Divisions of Rheumatology AOUC, Department of Experimental and Clinical Medicine University of Florence Florence Italy

26. Rheumatology Unit, DETO University of Bari Bari Italy

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1756-185X.15091

Reference16 articles.

1. Quality of life and therapeutic management of axial spondyloarthritis patients in Italy: a 12-month prospective observational study

2. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry

3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

4. Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension

5. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study